Issue Date: October 3, 2005
Qiagen buys Chinese firm
The Dutch nucleic acid specialist Qiagen has agreed to acquire Shenzhen PG Biotech, a Chinese developer of polymerase chain-reaction-based molecular diagnostic kits. Qiagen will buy all of PG's shares, 52% of which are held by state-owned institutions, for $14.5 million. Qiagen says the purchase is a “superb fit” with its own molecular diagnostics business. It recently acquired Artus, a German firm also focused on molecular diagnostics.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society